Metallo‐β‐lactamases (MBLs), produced by an increasing number of bacterial pathogens,
facilitate the hydrolysis of many commonly used β‐lactam antibiotics. There are no clinically …

The worldwide proliferation of life-threatening metallo-β-lactamase (MBL)-producing Gram-
negative bacteria is a serious concern to public health. MBLs are compromising the …

ABSTRACT Metallo-β-lactamase (MBL)-producing Enterobacteriaceae are of grave clinical
concern, particularly as there are no metallo-β-lactamase inhibitors approved for clinical …

A new scaffold, azolylthioacetamide, was constructed and assayed against metallo-β-
lactamases (MβLs). The obtained molecules specifically inhibited MβL ImiS, and 1c was …

Modern medicine is threatened by the global rise of antibiotic resistance, especially among
Gram-negative bacteria. Metallo-β-lactamase (MBL) enzymes are a particular concern and …

Multidrug-resistant bacterial infections have become in recent years an increasingly
worrisome problem in the medical community. The β-lactams are the most used antibiotics …

The emergence and spread of bacterial pathogens acquired metallo-β-lactamase (MBL) and
serine-β-lactamase (SBL) medicated β-lactam resistance gives rise to an urgent need for the …

Infections caused by multidrug resistant (MDR) bacteria are a major public health threat.
Carbapenems are among the most potent antimicrobial agents that are commercially …

The structural diversity in metallo-β-lactamases (MBLs), especially in the vicinity of the active
site, has been a major hurdle in the development of clinically effective inhibitors …

Antimicrobial resistance is one of the major problems in current practical medicine. The
spread of genes coding for resistance determinants among bacteria challenges the use of …